Activity Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.
Telix Japan to Present at Japanese Society of Nuclear Medicine Annual Scientific Meeting
Telix Japan is pleased to announce it will be presenting at the Annual Scientific Meeting of the Japanese Society of Nuclear Medicine (JSNM-JSNMT2020) to be held 12-14th November 2020 at Kobe International Conference Center.
Telix Completes Licence Agreement with German Cancer Research Center (DKFZ) for Image-Guided Prostate Surgery
Telix has secured an exclusive Intellectual Property licence agreement with the German Cancer Research Center (DKFZ) for a novel imaging technology in the field of image-guided surgery for prostate cancer.
Completion of Phase I Enrolment of Japanese Renal Cancer Study
Telix Pharmaceuticals Japan K.K. is pleased to announce the completion of Phase I enrolment of the Company’s Phase I/II ZIRDAC-JP study of Telix’s renal cancer diagnostic imaging product TLX250-CDx (89Zr-girentuximab) in Japan.
First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey
Telix and Eczacıbaşı-Monrol Nuclear Products Co. are pleased to announce that the first patients have been dosed in Telix’s Phase III ZIRCON clinical trial
Telix to Present at European Association of Nuclear Medicine 2020 Annual Congress
Telix sponsored a session at the recent EANM20 Satellite Symposium, entitled “Next Generation Imaging with PSMA-PET & More”. For those unable to attend, we are pleased to provide recordings of live presentations held on 29th October 2020.
Telix Pharmaceuticals to Participate at AusBiotech + Invest 2020
Telix Pharmaceuticals is pleased to announce we are participating at AusBiotech + Invest 2020 online conference to be held live 28th – 30th October 2020 and on-demand. Telix is pleased to be sponsoring the “Radiopharmaceuticals drug development: current and future trends” session on Thursday 29th October 2.15 pm – 3.00 pm (AEST).
Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)
First Patients Dosed in Clinical Trial of Novel Lung and Ovarian Cancer Theranostic
Telix announces first two patients dosed in phase I trial of lung & ovarian cancer theranostic